The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research

No abstract is available for this paper.

• Publication year

  2015

• Venue

  CNS Drugs

• Publication date

  2015-02-20

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1007/s40263-016-0349-0PMID 27290715
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Course of auditory vocal hallucinations in childhood: 11‐year follow‐up study

  2016cited by this paper
• Summary of product characteristics

  2016cited by this paper
• Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?

  2015cited by this paper
• Does Comorbid Disruptive Behavior Modify the Effects of Atomoxetine on ADHD Symptoms as Measured by a Continuous Performance Test and a Motion Tracking Device?

  2015cited by this paper
• The Efficacy of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Clinical Research

  2015cited by this paper
• Prevalence of auditory hallucinations in Norwegian adolescents: Results from a population-based study

  2015influential reference
• Pediatric loss of control eating syndrome: Association with attention-deficit/hyperactivity disorder and impulsivity.

  2015cited by this paper
• Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study.

  2015cited by this paper
• The relationship between ADHD and obesity: implications for therapy

  2014cited by this paper
• Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine pro-drug.

  2014cited by this paper
• Life-threatening QT prolongation in a boy with attention-deficit/hyperactivity disorder on atomoxetine

  2014cited by this paper
• Does Stimulant Pretreatment Modify Atomoxetine Effects on Core Symptoms of ADHD in Children Assessed by Quantitative Measurement Technology?

  2014cited by this paper
• Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology

  2014cited by this paper
• Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009–2011: Focus on clinical efficacy and safety

  2014cited by this paper
• Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression.

  2014cited by this paper
• Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study

  2014influential reference
• Predicting aggression in children with ADHD

  2014cited by this paper
• Comparative short term efficacy and tolerability of methylphenidate and atomoxetine in attention deficit hyperactivity disorder

  2014influential reference
• Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children

  2013cited by this paper
• Mortality, ADHD, and Psychosocial Adversity in Adults With Childhood ADHD: A Prospective Study

  2013cited by this paper
• A Meta-analysis of the Consistency of Atomoxetine Treatment Effects in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder from 15 Clinical Trials Across Four Geographic Regions

  2013cited by this paper
• Pediatrics Digest

  2013influential reference
• A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder

  2013cited by this paper
• Fast vs. Slow Switching from Stimulants to Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

  2013influential reference
• Methylphenidate amplifies the potency and reinforcing effects of amphetamines by increasing dopamine transporter expression

  2013cited by this paper
• Comparative Efficacy of Guanfacine Extended Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Applying Matching-Adjusted Indirect Comparison Methodology

  2013cited by this paper
• Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain – an in vivo study

  2013cited by this paper
• Self-Esteem Evaluation in Children and Adolescents Suffering from ADHD

  2013influential reference
• Successful Treatment with Atomoxetine of an Adolescent Boy with Attention Deficit/Hyperactivity Disorder, Extreme Obesity, and Reduced Melanocortin 4 Receptor Function

  2013cited by this paper
• Atomoksetin Tedavisi Alan Çocuk ve Ergenlerde Karaciğer Enzimleri ve Bilirubin Düzeyleri / Liver Enzymes and Bilirubin Levels during Atomoxetine Treatment in Children and Adolescents

  2013cited by this paper
• Epilepsy in a large cohort of children diagnosed with attention deficit/hyperactivity disorders (ADHD).

  2013cited by this paper
• Family functioning deficits in bipolar disorder and ADHD in youth.

  2013cited by this paper
• Atomoxetine tolerability in pediatric and adult patients receiving different dosing strategies.

  2013cited by this paper
• Long-Term Quality-of-Life and Functioning Comparison of Atomoxetine Versus Other Standard Treatment in Pediatric Attention-Deficit/Hyperactivity Disorder

  2013cited by this paper
• Attention-deficit/hyperactivity disorder and impairment in executive functions: a barrier to weight loss in individuals with obesity?

  2013cited by this paper
• Efficacy and Safety of Lisdexamfetamine Dimesylate and Atomoxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder: a Head-to-Head, Randomized, Double-Blind, Phase IIIb Study

  2013influential reference
• Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008.

  2013cited by this paper
• Long-term criminal outcome of children with attention deficit hyperactivity disorder.

  2013cited by this paper
• Suicide related events and attention deficit hyperactivity disorder treatments in children and adolescents: a meta-analysis of atomoxetine and methylphenidate comparator clinical trials

  2013influential reference
• A cohort study of the risk of seizures in a pediatric population treated with atomoxetine or stimulant medications

  2013influential reference
• Correlation between Epilepsy and Attention Deficit Hyperactivity Disorder: A Population-Based Cohort Study

  2013cited by this paper
• Atomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: a retrospective chart review

  2013influential reference
• ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis.

  2013cited by this paper
• Attention-deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study.

  2013influential reference
• Long-Term Treatment with Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms in Children and Adolescents with Autism Spectrum Disorder: An Open-Label Extension Study

  2013cited by this paper
• Meta-Analysis of Suicide-Related Behavior or Ideation in Child, Adolescent, and Adult Patients Treated with Atomoxetine

  2013influential reference
• PMH5 Systematic Review and Network Meta-Analysis of Treatments Used for Attention Deficit Hyperactivity Disorder (ADHD)

  2012cited by this paper
• Does Atomoxetine Improve Executive Function, Inhibitory Control, and Hyperactivity?: Results From a Placebo-Controlled Trial Using Quantitative Measurement Technology

  2012cited by this paper
• P-312 - Prognostic Factors of Improvement in Health Related Quality of Life in Children and Adolescents With Attention Deficit/hyperactivity Disorder, After Atomoxetine Treatment

  2012cited by this paper
• Improving Visual Memory, Attention, and School Function with Atomoxetine in Boys with Attention-Deficit/Hyperactivity Disorder

  2012influential reference
• Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States.

  2012cited by this paper
• Safety of Attention-Deficit/Hyperactivity Disorder Medications in Children: An Intensive Pharmacosurveillance Monitoring Study

  2012cited by this paper
• Cardiovascular Measures in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder Who Are New Users of Methylphenidate and Atomoxetine

  2012influential reference
• A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.

  2012influential reference
• The Prevalence of DSM-IV Attention-Deficit/Hyperactivity Disorder: A Meta-Analytic Review

  2012cited by this paper
• P.7.c.006 Changes in blood pressure and heart rate associated with atomoxetine treatment in attention-deficit/hyperactivity disorder

  2012cited by this paper
• Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.

  2012cited by this paper
• A systematic review of the safety information contained within the Summaries of Product Characteristics of medications licensed in the United Kingdom for Attention Deficit Hyperactivity Disorder. how does the safety prescribing advice compare with national guidance?

  2012cited by this paper
• Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD.

  2012cited by this paper
• Comparative effectiveness research using matching‐adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention‐deficit/hyperactivity disorder and comorbid oppositional defiant disorder

  2012cited by this paper
• Health-related quality of life in ADHD: a pooled analysis of gender differences in five atomoxetine trials

  2012influential reference
• Response to atomoxetine in boys with high‐functioning autism spectrum disorders and attention deficit/hyperactivity disorder

  2011influential reference
• PMH1 IS STIMULANT OR ATOMOXETINE UTILIZATION ASSOCIATED WITH NEUROLOGICAL ADVERSE EVENTS IN CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)? A RETROSPECTIVE ANALYSIS OF PROPENSITY SCORE MATCHED DATA

  2011cited by this paper
• Atomoxetine Versus Placebo in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder: A Double-Blind, Randomized, Multicenter Trial in Germany

  2011influential reference
• Improvement in Global Psychopathology Increases Quality of Life During Treatment of ADHD with Atomoxetine or Stimulants

  2011cited by this paper
• Atomoxetine and Methylphenidate Treatment in Children with ADHD: The Efficacy, Tolerability and Effects on Executive Functions

  2011cited by this paper
• Academic outcomes in Asian children aged 8–11 years with attention-deficit/hyperactivity disorder treated with atomoxetine hydrochloride

  2011cited by this paper
• A Comparison of Atomoxetine Administered as Once Versus Twice Daily Dosing on the School and Home Functioning of Children with Attention-Deficit/Hyperactivity Disorder

  2011influential reference
• Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder

  2011influential reference
• One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder

  2011cited by this paper
• PMH46 The Quality of Life of Children With ADHD and their Parents: Results of EQ-5D and Kidscreen-10

  2011cited by this paper
• Effect of atomoxetine on Tanner stage sexual development in children and adolescents with attention deficit/hyperactivity disorder: 18-month results from a double-blind, placebo-controlled trial

  2011influential reference
• How Oppositionality, Inattention, and Hyperactivity Affect Response to Atomoxetine Versus Methylphenidate

  2011cited by this paper
• A review on cognitive and brain endophenotypes that may be common in autism spectrum disorder and attention-deficit/hyperactivity disorder and facilitate the search for pleiotropic genes.

  2011cited by this paper
• Lower IQ is Associated with Decreased Clinical Response to Atomoxetine in Children and Adolescents with Attention-Deficit Hyperactivity Disorder

  2011cited by this paper
• Course of auditory vocal hallucinations in childhood: 5-year follow-up study.

  2011cited by this paper
• Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: analysis of Canadian open-label studies

  2011influential reference
• Effects of atomoxetine on cardiovascular functions and on QT dispersion in children with attention deficit hyperactivity disorder

  2011influential reference
• Transitioning to OROS® methylphenidate from atomoxetine is effective in children and adolescents with ADHD

  2011cited by this paper
• A Randomized, Open-Label Assessment of Response to Various Doses of Atomoxetine in Korean Pediatric Outpatients with Attention-Deficit/Hyperactivity Disorder

  2011cited by this paper
• Late Adolescent and Young Adult Outcomes of Girls Diagnosed With ADHD in Childhood: An Exploratory Investigation

  2011cited by this paper
• Core ADHD Symptom Improvement With Atomoxetine Versus Methylphenidate

  2011cited by this paper
• Cardiovascular Events and Death in Children Exposed and Unexposed to ADHD Agents

  2011influential reference
• Efficacy of Atomoxetine in Children With Severe Autistic Disorders and Symptoms of ADHD

  2011cited by this paper
• The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder.

  2011influential reference
• Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis

  2011cited by this paper
• ADHD drugs and serious cardiovascular events in children and young adults.

  2011influential reference
• Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials

  2010influential reference
• Very early predictors of adolescent depression and suicide attempts in children with attention-deficit/hyperactivity disorder.

  2010influential reference
• Minor differences in ADHD-related difficulties between boys and girls treated with atomoxetine for attention-deficit/hyperactivity disorder

  2010influential reference
• Quality of Life and Attention-Deficit/Hyperactivity Disorder Core Symptoms: A Pooled Analysis of 5 Non-US Atomoxetine Clinical Trials

  2010cited by this paper
• Efficacy of Strattera in Children and Adolescents with Attention Deficit Hyperactivity Disorder

  2010cited by this paper
• Safety of psychotropic drug prescribed for attention-deficit/hyperactivity disorder in Italy

  2010influential reference
• Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD

  2010influential reference
• Post Hoc Analysis: Early Changes in ADHD-RS Items Predict Longer Term Response to Atomoxetine in Pediatric Patients

  2010influential reference
• Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder.

  2010influential reference
• Epilepsy in children with attention-deficit/hyperactivity disorder.

  2010cited by this paper
• Does Placebo Response Differ between Objective and Subjective Measures in Children with Attention-Deficit/Hyperactivity Disorder?

  2010cited by this paper
• Effects of atomoxetine with and without behavior therapy on the school and home functioning of children with attention-deficit/hyperactivity disorder.

  2010influential reference
• Atomoxetine for attention deficit hyperactivity disorder in mental retardation.

  2010cited by this paper

• Risk of hospitalisation for first-onset psychosis or mania within a year of ADHD medication initiation in adults with ADHD

  2025cites this paper
• Mood Stabilizers for Treating Emotional Dysregulation in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD) with or Without Comorbid Bipolar Spectrum Disorders

  2025cites this paper
• A Review and an Update on Pharmacological Treatment of Children With Attention-Deficit/Hyperactivity Disorder

  2025cites this paper
• Effect of Atomoxetine on Mouse Isolated Vas Deferens Contractility

  2024cites this paper
• Quality of Life and Outcomes Associated with Adverse Effects in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder and Their Parents/Caregivers

  2024cites this paper
• La gestion pharmacologique du traitement du TDAH

  2024cites this paper
• The role of adrenergic neurotransmitter reuptake inhibitors in the ADHD armamentarium

  2024cites this paper
• Current nonstimulant medications for adults with attention-deficit/hyperactivity disorder

  2024cites this paper
• An Evaluation of Whether Routine QTc Interval Screening Is Necessary Prior to Starting ADHD Medications: Experience from a Large Retrospective Study

  2024cites this paper
• Risk of Newly Diagnosed Psychotic Symptoms in Youth Receiving Medications for Attention-Deficit/Hyperactivity Disorder

  2024cites this paper
• A Potential Role for Neuroinflammation in ADHD.

  2023cites this paper
• Pharmacotherapy for ADHD in children and adolescents: A summary and overview of different European guidelines

  2023cites this paper
• Role of Pharmacokinetics and Pharmacogenetics of Antidepressant-Induced Prolongation of the QT Interval and Torsade de Pointes in Patients with Mental Disorders

  2023cites this paper
• Analyzing Black Market Sales of the Second-Line ADHD Medication Atomoxetine

  2023cites this paper
• Atomoxetine-Associated Maculopapular Rash: A Case Report.

  2023cites this paper
• An updated safety review of the current drugs for managing ADHD in children

  2023cites this paper
• The combination of atomoxetine and oxybutynin for the treatment of obstructive sleep apnea in children with Down syndrome

  2023cites this paper
• Clinical practice guidelines for attention-deficit/hyperactivity disorder: recent updates

  2023cites this paper
• Novel Iron Oxide Nanoparticle-Fortified Carbon Paste Electrode for the Sensitive Voltammetric Determination of Atomoxetine

  2023cites this paper
• Long-term treatment of adult ADHD in a naturalistic setting: Clinical predictors of attrition, medication choice, improvement, and response

  2023cites this paper
• Growth Hormone and Thyroid Function in Children with Attention-Deficit/Hyperactivity Disorder Undergoing Drug Therapy.

  2022cites this paper
• No stimulant? No Problem: Analyzing Black Market Sales of Atomoxetine on StreetRx

  2022influential citation
• Eating Patterns and Dietary Interventions in ADHD: A Narrative Review

  2022cites this paper
• Viloxazine for the Treatment of Attention Deficit Hyperactivity Disorder.

  2022cites this paper
• Comorbidities in Youth with Bipolar Disorder: Clinical Features and Pharmacological Management

  2022cites this paper
• Updates in Pharmacologic Strategies in Adult Attention-Deficit/Hyperactivity Disorder.

  2022cites this paper
• A meta-analytic review of the impact of ADHD medications on anxiety and depression in children and adolescents

  2022cites this paper
• Personalization of pharmacological treatments for ADHD: Why it is advisable and possible options to achieve it.

  2022cites this paper
• Nonstimulant Treatments for ADHD.

  2022cites this paper
• Detection of atomoxetine and its metabolites in the urine by thin-layer chromatography and mass spectrometry

  2022cites this paper
• The Mechanism, Clinical Efficacy, Safety, and Dosage Regimen of Atomoxetine for ADHD Therapy in Children: A Narrative Review

  2022cites this paper
• Lifetime evolution of ADHD treatment

  2021cites this paper
• ADHD: Reviewing the Causes and Evaluating Solutions

  2021cites this paper
• ADHD and Bipolar Disorder in Adulthood: Clinical and Treatment Implications

  2021cites this paper
• Effects of methylphenidate on blood pressure, QT-interval, and cardiac output in ADHD diagnosed children: A three months’ follow-up study

  2021cites this paper
• Evidence-based pharmacological treatment options for ADHD in children and adolescents.

  2021cites this paper
• Perpetration of and Victimization in Cyberbullying and Traditional Bullying in Adolescents with Attention-Deficit/Hyperactivity Disorder: Roles of Impulsivity, Frustration Intolerance, and Hostility

  2021cites this paper
• Self-Reported Depressive Symptoms and Suicidality in Adolescents with Attention-Deficit/Hyperactivity Disorder: Roles of Bullying Involvement, Frustration Intolerance, and Hostility

  2021cites this paper
• Hepatic and Renal Impairment

  2021cites this paper
• Children and adolescents

  2021cites this paper
• Clinical Use of Clozapine Serum Level and Management of Adverse Effects in an Adolescent with Difficult to Treat Schizophrenia

  2021cites this paper
• Drug Treatment of Epilepsy Neuropsychiatric Comorbidities in Children

  2020cites this paper
• Neuroprotective Effects of Quercetin in Pediatric Neurological Diseases

  2020cites this paper
• The female side of pharmacotherapy for ADHD—A systematic literature review

  2020cites this paper
• ADHD in Childhood and Adolescence : Update 2020

  2020cites this paper
• ADHS im Kindes- und Jugendalter. Update 2020

  2020cites this paper
• A preliminary study of pharmacogenetic biomarkers for individuals with autism and gastrointestinal dysfunction

  2020cites this paper
• Antioxidants as a Potential Target against Inflammation and Oxidative Stress in Attention-Deficit/Hyperactivity Disorder

  2020cites this paper
• Central nervous system stimulants and drugs that suppress appetite

  2020cites this paper
• How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?

  2020cites this paper
• Psychotherapy, Atomoxetine or Both? Preliminary Evidence from a Comparative Study of Three Types of Treatment for Attention-Deficit/Hyperactivity Disorder in Children

  2020cites this paper
• Evaluation of the Effect of SPN-812 (Viloxazine Extended-Release) on QTc Interval in Healthy Adults.

  2020cites this paper
• Role of Oxidative Stress and Neuroinflammation in Attention-Deficit/Hyperactivity Disorder

  2020cites this paper
• Systematic Review: Medication Effects on Brain Intrinsic Functional Connectivity in Patients With Attention-Deficit/Hyperactivity Disorder.

  2020cites this paper
• Behandlung von ADHS bei Erwachsenen mit Atomoxetin

  2019cites this paper
• Medication for Attention-Deficit/Hyperactivity Disorder and Risk for Suicide Attempts.

  2019cites this paper
• Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents

  2019cites this paper
• ADHD With Comorbid Bipolar Disorders: A Systematic Review of Neurobiological, Clinical And Pharmacological Aspects Across The Lifespan.

  2019cites this paper
• Current follow‐up practices often fail to detect metabolic and neurological adverse reactions in children treated with second‐generation antipsychotics

  2019cites this paper
• Cardiovascular Effects of Drugs Used to Treat Attention-Deficit/Hyperactivity Disorder: Part 1: Epidemiology, Pharmacology, and Impact on Hemodynamics and Ventricular Repolarization.

  2019cites this paper
• Evaluation and Management of Elevated Blood Pressure in Children and Adolescents with Attention Deficit Hyperactivity Disorder

  2019cites this paper
• Natural Compounds for the Management of Parkinson's Disease and Attention-Deficit/Hyperactivity Disorder

  2018cites this paper
• Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial.

  2018cites this paper
• Basics of Psychopharmacological Management

  2018cites this paper
• Suicide risk in attention-deficit/hyperactivity disorder.

  2018cites this paper
• Pharmacologic management of attention deficit hyperactivity disorder in children and adolescents: a review for practitioners.

  2018cites this paper
• Effects of Atomoxetine on Height and Weight in Korean Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Retrospective Chart Review

  2018cites this paper
• Brief report of efficacy and side effect profile of crossing over to modified-release capsules of methylphenidate in ADHD patients receiving other treatments: case series

  2017cites this paper
• The Revised Korean Practice Parameter for the Treatment of Attention-Deficit Hyperactivity Disorder ( IV )-Non-Pharmacologic Treatment

  2017cites this paper
• The effect of atomoxetine, a selective norepinephrine reuptake inhibitor, on respiratory arrest and cardiorespiratory function in the DBA/1 mouse model of SUDEP.

  2017cites this paper
• Development of the methods for atomoxetine identification suitable for the chemical and toxicological analysis

  2017cites this paper
• The Revised Korean Practice Parameter for the Treatment of Attention-Deficit Hyperactivity Disorder (IV) - Non-Pharmacologic Treatment -

  2017cites this paper
• [Pregnancy and breastfeeding].

  2016cites this paper
• Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children

  2016cites this paper
• Negligible Effects of Acute Atomoxetine Administration on Visual Working Memory in the Macaque Monkey

  2016cites this paper
• Post Hoc Analysis of Potential Predictors of Response to Atomoxetine for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder using an Integrated Database

  2016cites this paper
• Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder

  2015cites this paper
• Pharmacological treatment of attention-deficit/hyperactivity disorder: assessing outcomes

  2015cites this paper
• Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability.

  2015cites this paper
• Clinical Practice Guideline for Patients with Attention Deficit/Hyperactivity Disorder

  2014cites this paper
• The management of attention-deficit hyperactivity disorder in children: updated 2022

  2012cites this paper